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"1043-111 Dual-Site or Bi-Atrial Pacing Does Not Enhance Atrial 
Activation as Compared to Pacing From Novel Single 
Right Atr ia l  Sites in Humans 
Kevin R. Camobell. Jeffrey M. Whitehill, Aaron Hesselson, Peter Gallagher, Tristram D. 
Bahnson, Duke University Durham, North Carolina. 
Introduction: Atrial based pacing for prevention of atrial fibrillation using standard and 
novel pacing configurations is under investigation. A possible anti-arrhythmic mechanism 
of pacing is to enhance bi-atrial activation and decrease dispersion of refractoriness. To 
determine whether dual site pacing (pacing from the distal right atdal (RA) appendage 
plus coronary sinus os), or bi-atrial pacing (pacing from the distal RA appendage plus 
distal coronary sinus) results in shortened atdal activation time (AAT) as compared to 
pacing from single RA sites, 19 patients (age 50±19 y) undergoing standard catheter 
ablation procedures were studied. 
Methods: Pacing at 600 ms was accomplished in each subject from the proximal RA 
appendage, distal RA appendage, high RA septum, coronary sinus os, and using dual 
site and bi-atdal pacing. AAT was assessed by measuring P-wave duration from high- 
resolution (50-400 mrn/s; 1-5 mV/cm) 12-lead rhythm stdps. 
Results: AAT dudng sinus rhythm (116.7±13.2 ms, mean±S.D.), and during single site 
pacing from the high septum (118.1±13.3), proximal appendage (116.4±11.2), coronary 
sinus os (118.9±15.9), and using dual site (110±12.8) or bi-atrial (107.9±14.1) pacing 
was the same (ANOVA, p>0.07). AAT during pacing from the distal RA appendage 
(129.4±21.6) was significantly greater than with pacing from any other site (ANOVA, 
p=0.001, T-test P=0.01). Dual site or bi-atdal pacing did not result in significantly shorter 
atrial activation times compared with pacing from the 'best' single site (P=0.54, 0.22 
respectively). 
Conclusions: 1) There is no significant enhancement of AAT using multi-site pacing in 
these individuals with normal intra- and inter-atrial conduction compared to RA pacing 
from a single site that yields rapid atrial activation. 2) A map-guided single RA pacing site 
can provide the benefits of muiti-sita pacing on atrial activation in such individuals without 
the need for multiple RA pacing leads. 3) Further studies are required to determine 
whether multi-site pacing provides added antiarrhythmic benefit compared to pacing from 
selected single RA pacing sites in individuals with atrial fibrillation and intact atrial con- 
duction. 
1043-111A Mult ie i te  or  Septal  Pacing for Arrhythmla Suppression 
in an Exper imenta l  Model  o f  Paroxysmal  Atr ia l  
F ibr i l lat ion? 
Ruedioer Becker. Alexander Bauer, Julia C. Senges, Frederik Voss, Wolfgang Schoels, 
University of Heidelberg, Heidelberg, Germany 
Methods: To investigate whether multisite and septal pacing suppress paroxysmal atdal 
fibrillation (AF) in an expedmental model, sterile right atrial pericarditis was induced in 12 
foxhounds to provide an anatomical substrate. As a trigger mechanism, atdal extrasysto- 
les were simulated by constant asynchronous pacing at a cycle length (CL) of 1000 ms 
from randomly selected dght or left atrial electrodes, contained within a custom-designed 
epicardial multielectrode with 128 bipoles. Additionally, a transvenous pacing lead was 
screwed into the interatdal septum. Four electrodes located in the high and low right 
(HRA/LRA) and left atrium (HLNLLA) were selected for multisita stimulation. Constant 
pacing at a CL 30 ms below sinus rate was applied from the following pacing sita(s) in 
random order: 1) HRA, 2) HRA + LRA, 3) HRA + LLA, 4) HRA + LRA + LLA, 5) HRA + 
LRA + HLA + LLA, and 6) septaL Number and duration of AF episodes with or without 
preventive pacing were studied during 10 rain intervals, separated by 5 min pauses, 
respectively. 
Results: The efficacy in suppressing AF increased with the number of pacing sites. Sin- 
gle-site septal pacing was as efficient as quadruple-site pacing. The data are summa- 
rized in the table below (*=p<0.05 vs. HRA; Tukey Kramer HSD test). 
Conclusion: In this expedmental model, preventive atrial pacing reduced the number of 
AF episodes, most efficiently with an increasing number of simultaneously paced sites or 
with a sin.91e pacing site located septally. 
Pacing sita(s) AF episodes (n) Episode duration (s) 
HRA 14.3±10.2 24±38 
HRA+LRA 7.5±8.3 22±27 
HRA+LLA 8.4±7.4 19±52 
HRA+LRA+LLA 7.1±6.5 12±19 
HRA+LRA+HLA+LLA 3.9±4.2* 37±81 
Septal 3.7±3.6* 37±75 
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1066-103 Left  Atr ia l  Appendage L igat lon  Dur ing Mltral  Valve 
Surgery  May  Increase the Risk of Late Thromboembolic 
Events 
Nour M. Juratli, Bruce L. Wilkoff, Patrick J. Tchou, Delos M Cosgrove, Bruce W. Lytle, 
Mina K. Chung, Michael S. Lauer, Luther T. Clark, Mark J. Niebauer, Walid Saliba, Robert 
A. Schweikert, Andrea Natale, Cleveland Clinic Foundation, Cleveland, Ohio. 
Background: The need for non-pharmacological treatment o prevent thromboembolic 
events (TEl in atrial fibrillation (AF) is increasing. Left atrial appendage (LAA) ligation 
during mitrat valve (MV) surgery was suggested as an alternative treatment to anticoagu- 
lation with warfarin, but the role of this surgical procedure is still controversial. Methods: 
Between 5/93 and 11/98 136 patients (pts) underwent LAA ligation during MV surgery. 
Complete follow up was available on 114 pts, There were 67 (58.8%) females and 47 
(41.2%) males with a mean age of 61.1 + 12.3 yrs and a mean LVEF of 46.7 ± 12.3%. 
The MV was replaced with bioprosthetic valve in 36 (31.6%) pts or mechanical in 27 
(23.7%) pts and repaired in 51 (44.7%) pts. A control group of 146 pts who underwent 
MV surgery without LAA ligation were selected randomly and found to match for age, 
sex, LVEF, type of valve surgery, left atrial size, HTN, DM, and smoking history. Late TE 
was defined as stroke, transient ischemic attack, or peripheral embolism occurring 48 
hours after the surgery. Cardiothoracic surgery database and telephone contact were 
used to assess the incidence of late TE. Results: Over a follow up period of 1318 + 481 
days 14 (12.3%) pts had TE in LAA ligation group vs 9 (6.2%) pts in the control group 
over a follow up penod of 1705 ± 650 days. Late TE by Kaplan-Meier curves for the two 
groups differed significantly for the entire follow up pedod with a p value of 0.034. The 
one year rate of TE in LAA ligation group was 8.8 ± 2.7% vs. 2.7 ± 1.4% in the control 
group. No warfarin therapy or subtherapeutic anticoagulation was found in 23 pts out of 
24 pts during TE. Among pts who were not prescribed warfadn prior to discharge home 
6/40 (15%) pts had TE in I.AA ligation group compared to 2/60 (3.3%) in the control 
group (p=0.023). There was no difference in late TE between the two groups among 
patients who were prescribed warfarin prior to discharge home 7/67 (11.5%) pts in LAA 
ligation group vs. 7/70 (10%) in control group (p=0.66). Conclusion: In this group of 
patients LAA tigation does not provide adequate protection from late thromboembolic 
events in the absence of effective anticoagulation with warfarin. 
1066-104 Prevent ion  of  Post -Cardiac Surgery  Atr ia l  F ibr i l lat ion Is 
Not  Assoc ia ted  With Decrease in Post-Operative 
Stroke: Meta-Ana lys is  
Euoene Crystal. Stuart J. Connolly, Khaled Sleik, Trecy J. Ginger, Salim Yusuf, McMaster 
University Hamilton, Ontario, Canada, Green Lane Hospital, Auckland, New Zealand. 
Post-operative atrial fibdllation (POAF) has been associated with increased rate of post- 
operative stroke. However, it is far from certain that the POAF is an actual cause of post- 
cardiac surgery stroke, because other intra- and extra-cardiac sources of embolism are 
common. No study has convincingly demonstrated that a decrease in POAF prevents 
post-cardiac surgery stroke. Therefore, we performed meta-analysis of randomized con- 
trolled trials on POAF prevention by drugs (beta-blockers, sotalol and amiodarone) and 
pacing, with the end-point of in-hospital post-operative stroke. The identification of trials 
and data derivation were performed in accordance to Cochrane group methodology. 
Results. The data regarding stroke were available in 12 randomized control trials, with 
the total population of 2683 patients. Most of trials excluded patients with low left ventdc- 
ular ejection fraction and other groups at increased ped-operative risk. 1064 pts were 
randomized to amiodarone, 347 to sotalol, 1077 to other beta-blockers and 195 to the 
pacing or control treatment. The control groups received routine care, or placebo. The 
occurrence of POAF decreased significantly from 39% in control group to 25% in treat- 
ment group (OR 0.45, 95%CI 0.35, 057). The incidence of post-operative stroke was 
1.2% in control vs. 1.2% in intervention group (OR 0.94,95%CI 0.46, 1.92). 
Conclusion. The enrolled population had low risk of peri-operative stroke. In this meta- 
analysis, decrease in occurrence of POAF was not associated with change in the rate of 
post-operative stroke, although the power of this study was still insufficient to prove dif- 
ferences in range below 1%. 
1066-105 Predictors of Warfarin Use in Atrial Fibrillation: Insights 
From the FRACTAL Regist ry  
Matthew R. Reynolds, Mark E. Josephson, P. A. Friedman, T. Hadjis, R. Lemery, T. D. 
Bahnson, D. S. Cannom, Peter Zimetbaum, Beth Israel Deaconess Medical Canter, 
Boston, Massachusetts. 
Background: Warfarin is underused for stroke prevention in atrial fibrillation (AF). Previ- 
ous studies have shown that some stroke risk factors such as prior stroke or congestive 
heart failure (CHF) are predictive of warfarin use, while other stroke risk factors are not. 
Prior studies have lacked longitudinal observation, and little is known about whether anti- 
coagulation rates vary by physician specialty type. 
Methods: We analyzed warfarin use in 1005 subjects enrolled in the Fibrillation Registry 
Assessing Costs, Therapies, Adverse events, and Lifestyle (FRACTAL), an observational 
cohort study of new onset atrial fibrillation. Possible determinants of warfarin use at 
enrollment and 12 months later were evaluated using logistic regression. 
